Post by BIMOVIS

𝗜𝘀 𝘆𝗼𝘂𝗿 𝗜𝗣 𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗲𝗱 𝗯𝘆 𝗮 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗼𝗿 𝗮 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲? 𝗪𝗵𝘆 𝘁𝗵𝗲 "𝗚𝗲𝗻𝘂𝘀 𝗖𝗹𝗮𝗶𝗺" 𝗷𝘂𝘀𝘁 𝗴𝗼𝘁 𝗵𝗮𝗿𝗱𝗲𝗿 𝗮𝗻𝗱 𝗵𝗼𝘄 𝘁𝗼 𝘄𝗶𝗻 𝗶𝘁. The era of "easy" antibody patents is over. Recent Supreme Court rulings, such as Amgen v. Sanofi, have sent a clear message to the biotech industry: traditional large-scale sequencing and limited epitope mapping are no longer sufficient to "demonstrate the general quality of the genus". 𝗧𝗵𝗲 𝗣𝗿𝗼𝗯𝗹𝗲𝗺: For years, companies relied on identifying conserved residues in CDR-regions through sequencing. However, these claims are easily bypassed and are increasingly invalidated by the USPTO and courts. If you only provide data for one or two antibodies, you haven’t proven you own the whole "genus". 𝗧𝗵𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻: 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗕𝗶𝗼𝗹𝗼𝗴𝘆 + 𝗜𝗻 𝗦𝗶𝗹𝗶𝗰𝗼 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 To build a "bulletproof" patent in the 21st century, we must move beyond the sequence. By combining high-resolution structure determination (X-ray or Cryo-EM) with massive computational simulations, we can now: Map the Exact Interaction: Determine the precise paratope-epitope complex at resolutions of 1.5-3.5 Å. 𝗣𝗿𝗲𝗱𝗶𝗰𝘁 𝘁𝗵𝗲 𝗨𝗻𝗸𝗻𝗼𝘄𝗻: Use physics-based MD simulations to calculate the binding affinity and stability of up to 10¹⁴ possible paratope variations. 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗲 𝘁𝗵𝗲 𝗚𝗲𝗻𝘂𝘀: Provide the USPTO with empirical evidence of every promising variant, making your patent claims significantly harder to bypass. Structural biology isn't just a research tool anymore; it is the bedrock of intellectual property validation. Are you still relying on 20th-century methods for 21st-century patents? Let’s discuss how BIMOVIS and PTNG Scientific are redefining antibody characterization. #StructuralBiology #AntibodyDiscovery #IPStrategy #Biotech #CryoEM #DrugDevelopment